Odonate Therapeutics, Inc. (ODT) |
| 1.12 -0.05 (-4.27%) 04-24 15:47 |
| Open: | 1.16 |
| High: | 1.2 |
| Low: | 1.1107 |
| Volume: | 716,440 |
| Market Cap: | 0(M) |
| PE Ratio: | -0.41 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 28.41 |
| 52w Low: | 0.85 |
Odonate Therapeutics, Inc. functions as a pharmaceutical enterprise, dedicating its efforts to the creation of innovative therapeutic agents for cancer treatment. A prominent compound within its development pipeline is tesetaxel, an orally administered chemotherapy drug. This agent is currently advancing through Phase III clinical trials, specifically under investigation for its application in individuals with metastatic breast cancer. Established in 2013, the company's operations are headquartered in New York, New York.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Fri, 07 Jan 2022
Odonate Announces Expected Delisting of Its Stock - Business Wire
Tue, 11 May 2021
3 Net Current Asset Value Stock Picks - GuruFocus
Mon, 22 Mar 2021
Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel - Business Wire
Mon, 17 Jun 2019
Weekly CEO Buys Highlight - GuruFocus
Tue, 14 Jul 2026
Tue, 14 Jul 2026
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
